Schizophrenia Clinical Trials in Austin, Texas

13 studies are recruiting for schizophrenia in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Austin, Texas
    Locations
    19 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07105111 on ClinicalTrials.gov

  2. A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

    Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult part…

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Community Clinical Research - Cross Park Drive /ID# 272977, Austin, Texas
    Locations
    7 in total
    Run by
    AbbVie

    See if you can join NCT07145918 on ClinicalTrials.gov

  3. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Local Institution - 0049, Austin, Texas
    Locations
    59 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07686263 on ClinicalTrials.gov

  4. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

    A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

    Stage
    Phase 1
    Ages
    18 to 55
    Site
    Community Clinical Research, Austin, Texas
    Locations
    8 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07061288 on ClinicalTrials.gov

  5. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Clinical Site, Austin, Texas
    Locations
    42 in total
    Run by
    MapLight Therapeutics

    See if you can join NCT07459647 on ClinicalTrials.gov

  6. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

    The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

    Stage
    Phase 1
    Ages
    18 to 55
    Site
    Community Clinical Research, Inc., Austin, Texas
    Locations
    8 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07615426 on ClinicalTrials.gov

  7. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage
    Not phased
    Ages
    18 and older
    Site
    Local Institution - 0016, Austin, Texas
    Locations
    55 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

  8. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Community Clinical Research Inc, Austin, Texas
    Locations
    73 in total
    Run by
    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

  9. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Austin, Texas
    Locations
    57 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

  10. A Study to Evaluate the Effect of KarXT on Urological Safety

    The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

    Stage
    Phase 4
    Ages
    18 to 65
    Site
    Local Institution - 0001, Austin, Texas
    Locations
    13 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07221877 on ClinicalTrials.gov

  11. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Austin, Texas
    Locations
    21 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

  12. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Vanda Investigational Site, Austin, Texas
    Locations
    22 in total
    Run by
    Vanda Pharmaceuticals

    See if you can join NCT06961968 on ClinicalTrials.gov

  13. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Reviva site, Austin, Texas
    Locations
    18 in total
    Run by
    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.